Mechanisms of action of IVIG in autoimmune and inflammatory disorders: Recent developments;Immunoglobulines intraveineuses dans les maladies auto-immunes et inflammatoires : au-delà d'une simple substitution

Transfusion Clinique et Biologique

Volumn 16, Issue 2, 2009, Pages 75-79

  Galeotti, C ^a,b   Maddur, M S ^a,b   Kazatchkine, M D ^a,b   Mouthon, L ^c,d   Kaveri, S V ^a,b  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c IFR Alfred Jost   (France)

^d Service de Medecine Interne   (France)

Author keywords

Autoimmunity; Inflammation; Intravenous immunoglobulins; Sialylated IgG F

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL FUNCTION; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; GRANULOCYTE; IMMUNOMODULATION; INFLAMMATION; NATURAL KILLER CELL; REGULATORY MECHANISM; SHORT SURVEY; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; DENDRITIC CELLS; GRANULOCYTES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; KILLER CELLS, NATURAL; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 67349200765     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2009.03.009     Document Type: Short Survey

References (41)

1. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
2. Imbach P., Barandun S., d'Apuzzo V., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981) 1228-1231
3. Bayry J., Kazatchkine M.D., and Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 3 (2007) 120-121
4. Elovaara I., Apostolski S., van Doorn P., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15 (2008) 893-908
5. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26 (2008) 513-533
6. Anthony R.M., Nimmerjahn F., Ashline D.J., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376
7. Shoenfeld Y., Rauova L., Gilburd B., et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14 (2002) 1303-1311
8. Blank M., Anafi L., Zandman-Goddard G., et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 19 (2007) 857-865
9. Tha-In T., Bayry J., Metselaar H.J., et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29 (2008) 608-615
10. Akilesh S., Petkova S., Sproule T.J., et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328-1333
11. Hansen R.J., and Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100 (2002) 2087-2093
12. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37 (2000) 261-266
13. Debre M., Bonnet M.C., Fridman W.H., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342 (1993) 945-949
14. Abe J., Jibiki T., Noma S., et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 174 (2005) 5837-5845
15. Kaneko Y., Nimmerjahn F., Madaio M.P., et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789-797
16. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
17. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
18. Kaveri S.V., Lacroix-Desmazes S., and Bayry J. The anti-inflammatory IgG. N Engl J Med 359 (2008) 307-309
19. Dimitrov J.D., Bayry J., Siberil S., et al. Sialylated therapeutic IgG: A sweet remedy for inflammatory diseases?. Nephrol Dial Transplant 22 (2007) 1301-1304
20. Anthony R.M., Wermeling F., Karlsson M.C., et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105 (2008) 19571-19578
21. Bayry J., Bansal K., Kazatchkine M.D., et al. DC-SIGN and {alpha}2, 6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci USA 106 (2009) E24
22. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 45 (2008) 4073-4079
23. Lutz H.U., Stammler P., Bianchi V., et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103 (2004) 465-472
24. Crow A.R., Song S., Freedman J., et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102 (2003) 558-560
25. Crow A.R., Song S., Semple J.W., et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood 109 (2007) 155-158
26. Raju R., and Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: Effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128 (2005) 1887-1896
27. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., et al. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 3 (2007) 262-272
28. Pigard N., Elovaara I., Kuusisto H., et al. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol (2009)
29. Prasad N.K., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
30. Ephrem A., Chamat S., Miquel C., et al. Expansion of CD4 + CD25 + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111 (2008) 715-722
31. Kessel A., Ammuri H., Peri R., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179 (2007) 5571-5575
32. Bayry J., Lacroix-Desmazes S., Delignat S., et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 3497-3502
33. Bayry J., Lacroix-Desmazes S., Carbonneil C., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
34. van Mirre E., Teeling J.L., van der Meer J.W., et al. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol 173 (2004) 332-339
35. von Gunten S., Schaub A., Vogel M., et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (2006) 4255-4259
36. von Gunten S., Vogel M., Schaub A., et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 119 (2007) 1005-1011
37. Chang J., Shi P.A., Chiang E.Y., et al. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 111 (2008) 915-923
38. Jarius S., Eichhorn P., Albert M.H., et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 109 (2007) 4376-4382
39. Kwak J.Y., Kwak F.M., Ainbinder S.W., et al. Elevated peripheral blood natural killer cells are effectively down-regulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 35 (1996) 363-369
40. Finberg R.W., Newburger J.W., Mikati M.A., et al. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr 120 (1992) 376-380
41. Tha-In T., Metselaar H.J., Tilanus H.W., et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110 (2007) 3253-3262